What BPC-157 is
BPC-157 is a synthetic pentadecapeptide — fifteen amino acids — corresponding to a partial sequence of Body Protection Compound, a protein isolated from human gastric juice. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, notable for a proline-rich stretch that contributes to its conformational rigidity and to its reported stability.
That stability is the compound's most distinctive physical property. Short peptides are generally fragile in proteolytic environments; BPC-157 is reported to remain intact in human gastric juice, which is unusual enough to have driven much of the early interest in it.
Molecular profile
| Property | Value |
|---|---|
| Sequence | GEPPPGKPADDAGLV |
| Length | 15 amino acids |
| CAS number | 137525-51-0 |
| Molecular formula | C62H98N16O22 |
| Molecular weight | ~1,419.5 Da |
| Common salt form | Acetate |
| Appearance | White lyophilised powder |
Research context
The BPC-157 literature is largely preclinical and concentrated in tissue repair models. Reported lines of investigation include:
- Angiogenesis — effects on endothelial cell migration and tube formation in vitro, with reported involvement of VEGF receptor 2 signalling.
- Tendon and ligament models — fibroblast migration, adhesion and survival in cultured tendon explants.
- Gastrointestinal models — mucosal integrity in experimental injury.
- Nitric oxide pathway interaction — a recurring theme across the literature, with reported modulation of NO system activity.
The evidence base is dominated by rodent work from a relatively small number of research groups, and human clinical data is limited. That is a genuine characterisation of the literature rather than a caveat added for form.
Supplied for in-vitro laboratory research only. No therapeutic claim is made and no dosing or administration guidance is provided.
Analytical notes
At 15 residues BPC-157 is a comparatively straightforward peptide to synthesise and to characterise, which means the analytical questions are about the manufacturing rather than about the method.
Deletion sequences are the impurity class of interest. A synthesis that fails to couple one residue produces a 14-mer differing by a single amino acid — close enough in retention time that a lazily integrated chromatogram can absorb it into the main peak, and different enough in mass that mass spectrometry catches it immediately.
Salt form changes what the label means. Acetate and arginate salts of the same peptide carry different counter-ion masses, so 10 mg of gross material is a different quantity of peptide depending on which you have. The certificate should state the salt form and, ideally, the net peptide content — the difference between net peptide content and purity is where most concentration errors originate.
Handling and storage
Store sealed at −20 °C, protected from light and moisture. Allow the vial to reach room temperature before opening. BPC-157 is more forgiving to reconstitute than the lipidated metabolic peptides, but the same practice applies: run diluent down the vial wall, swirl rather than shake, and store the resulting solution at 2–8 °C protected from light.
What we supply
Released against a ≥99% purity specification, with in-house HPLC and mass spectrometry on every batch and a batch-specific Certificate of Analysis recording the salt form as well as the purity. Select batches additionally receive independent third-party purity verification.